YPSN logo

Ypsomed Holding Stock Price

Symbol: SWX:YPSNMarket Cap: CHF 5.3bCategory: Healthcare

YPSN Share Price Performance

CHF 392.00
-7.50 (-1.88%)
20.8% undervalued intrinsic discount
CHF 495.00
Fair Value
CHF 392.00
-7.50 (-1.88%)
20.8% undervalued intrinsic discount
CHF 495.00
Fair Value
Price CHF 392.00
AnalystHighTarget CHF 495.00
AnalystConsensusTarget CHF 455.54
AnalystLowTarget CHF 356.00

YPSN Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value CHF 495.00 20.8% undervalued intrinsic discount

Connected Self-Injection Devices Will Redefine Chronic Care Globally

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value CHF 455.54 13.9% undervalued intrinsic discount

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value CHF 356.00 10.1% overvalued intrinsic discount

Overcapacity And Regulatory Challenges Will Limit Future Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent YPSN News & Updates

No updates

Ypsomed Holding AG Key Details

CHF 748.9m

Revenue

CHF 456.8m

Cost of Revenue

CHF 292.1m

Gross Profit

CHF 204.6m

Other Expenses

CHF 87.5m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Nov 12, 2025
Earnings per share (EPS)
6.41
Gross Margin
39.00%
Net Profit Margin
11.68%
Debt/Equity Ratio
39.3%

Ypsomed Holding AG Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About YPSN

Founded
1984
Employees
2644
CEO
Simon Michel
WebsiteView website
www.ypsomed.com

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Swiss Market Performance

  • 7 Days: 0.2%
  • 3 Months: -0.8%
  • 1 Year: 0.9%
  • Year to Date: 2.4%
In the last week, the market has stayed flat, however the Financials sector stood out, gaining 3.5%. In line with that, the market has also been flat over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading